title: [Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
abstract: Case 1 involved a 63-year-old woman who had multiple hepatocellular carcinomas (HCC) associated with hepatitis C virus infection. She was treated with hepatic arterial infusion chemotherapy (HAIC) and transcatheter arterial chemoembolization (TACE), followed by oral administration of sorafenib (200 mg/day). However, a lesion on the left lateral segment of the liver enlarged rapidly. Laparoscopic left lateral sectionectomy was performed. Histopathological examination revealed combined hepatocellular and cholangiocellular carcinoma. Case 2 involved a 54-year-old man who had multiple recurrent HCCs associated with hepatitis C virus infection after undergoing hepatectomy twice. Oral administration of sorafenib (200 mg/day) was initiated. The intrahepatic lesions decreased in size, but metastasis in an enlarged lymph node behind the portal vein was suspected. Laparoscopic partial hepatectomy and lymph node dissection were performed. HCC metastasis in the lymph node and partial necrosis in the intrahepatic lesions were identified histopathologically. Case 3 involved a 56- year-old man who had multiple recurrent HCCs associated with hepatitis C virus infection. TACE was performed thrice, and oral administration of sorafenib( 400-600 mg/day) was initiated. The lesion in the right lateral segment of the liver decreased in size but lesions in the left lateral segment were enlarged. Therefore, laparoscopic left hemihepatectomy was performed.
authors.affiliation: Dept. of Hepato-Biliary-Pancreatic Surgery, Osaka City General Hospital.
authors.forename: Hisateru
authors.initials: H
authors.lastname: Komatsu
authors.forename: Tadashi
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: Shintaro
authors.initials: S
authors.lastname: Kodai
authors.forename: Akishige
authors.initials: A
authors.lastname: Kanazawa
authors.forename: Sadatoshi
authors.initials: S
authors.lastname: Shimizu
authors.forename: Sadaaki
authors.initials: S
authors.lastname: Yamazoe
authors.forename: Go
authors.initials: G
authors.lastname: Ohira
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Nakajima
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakai
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Kiyohide
authors.initials: K
authors.lastname: Kioka
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006498:Hepatectomy; D006801:Humans; D010535:Laparoscopy; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D012008:Recurrence; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib